Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

Digestive Diseases and Sciences

Volumn 52, Issue 6, 2007, Pages 1540-1547

  Sjogren, Maria H ^a   Sjogren Jr , Robert ^b   Lyons, Michael F ^c   Ryan, Michael ^d   Santoro, John ^e   Smith, Coleman ^f   Reddy, K Rajender ^g   Bonkovsky, Herbert ^h   Huntley, Brooke ^a   Faris Young, Sima ⁱ  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c Tacoma Digestive Disease Center   (United States)

^d Digestive and Liver Disease Specialists   (United States)

^e Atlantic Gastroenterology Associates Egg Harbor Township New Jersey   (United States)

^f Minnesota Gastroenterology   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ InterMune Inc   (United States)

Author keywords

African American; Depression; Interferon alfacon 1; Quality of life; Viral hepatitis; Viral load

Indexed keywords

CONSENSUS INTERFERON; PEGINTERFERON ALPHA2B; RIBASPHERE; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; QUALITY OF LIFE; RIBAVIRIN; VIRAL LOAD;

EID: 34248661259     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9757-9     Document Type: Article

References (27)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341(8):556-562
2. Gish RG, Afdhal NH, Dieterich DT, Reddy KR (2005) Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 3(4):311-318
3. Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36(5; Suppl 1):S21-S29
4. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39(4):1147-1171
5. Fried MW, Shiffman ML, Reddy KR, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
6. Manns MP, McHutchison JG, Gordon SC, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958-965
7. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39(6):1702-1708
8. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350(22):2265-2271
9. Sjogren MH, Sjogren R, Holtzmuller K, et al. (2005) Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 50(4):727-732
10. Blatt LM, Mutchnick MG, Tong MJ, et al. (2000) Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7(3):196-202
11. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125(8):634-639
12. Blatt LM, Davis JM, Klein SB, Taylor MW (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16(7):489-499
13. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 12(1):55-59
14. Tong MJ, Reddy KR, Lee WM, et al. (1997) Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26(3):747-754
15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
16. Clark CH, Mahoney JS, Clark DJ, Eriksen LR (2002) Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 40(3):361-369
17. Kleinman L, Zodet MW, Hakim Z, et al. (2000) Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 9(5):499-508
18. Ware JE, Jr., Bayliss MS, Mannocchia M, Davis GL (1999) Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 30(2):550-555
19. Leevy CB, Chalmers CP, Blatt LM (2005) Predictive model and sustained virologic response for PEG IFN-alfa-2+ weight-based ribavirin nonresponders re-treated with IFN alfacon-1 + weight-based ribavirin. Gastroenterology 128:S1538
20. Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25-31
21. Perelson AS, Herrmann E, Micol F, Zeuzem S (2005) New kinetic models for the hepatitis C virus. Hepatology 42(4):749-754
22. Fish EN, Banerjee K, Stebbing N (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res 9(1):97-114
23. Klein SB, Blatt LM, Taylor MW (1993) Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a. J Interferon Res 13(5):341-347
24. Blatt LM, Radhakrishnan R, Seiwert S, Tan H, Cheung E (2005) Biological characterization of PEG alfacon-1 in vitro: comparison of biological potency to the parent molecule interferon alfacon-1. Gastroenterology 128:S915
25. Schaefer M, Schwaiger M, Garkisch AS, et al. (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42(6):793-798
26. Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36(5; Suppl 1):S237-S244
27. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121-1123